Frontage adds 6,200 Square Meters of Laboratory Space to Expand Large Molecule Bioanalytical and Central Laboratory Operations, New Biological Laboratory for Drug Activity Screening
Frontage Laboratories in Exton is offering COVID-19 RT-PCR and IgM (Antibody) testing with fast turnaround time
Our highly experienced central lab team has successfully developed COVID-19 RT-PCR and IgM testing capability at our headquarters located at 700 Pennsylvania Drive in Exton, PA.
Frontage Laboratories: Solving the Most Complex Drug Discovery Challenges
Frontage Laboratories, is a value-added partner with a focus on solving its customers’ most signiﬁcant and complex drug discovery and development challenges. The organization’s scientiﬁc knowledge base, technical expertise and reputation for high quality services have been integral to its ability to enter into strong long-term strategic relationships and partnerships with its key customers.
Frontage receives “2020 Top 20 CRO enterprises in China”
On September 10, 2020, "2020 China Pharmaceutical and health industry development conference and the fourth China Pharmaceutical R & D Innovation Summit (PDI)" announced "2020 top 20 Chinese R & D cro enterprises". Frontage was successfully selected into the "2020 Top 20 CRO enterprises in China".
Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.
Daniel has over 23 years’ experience in biotech/pharmaceutical and the CRO industry. Prior to Frontage, he was COO of Phanes Therapeutics. He also held various leadership positions with increasing scientific and managerial responsibilities, including CEO of United-Power Pharmatech (UPP), a biologics bioassay CRO in specializing in biologics/biosimilars PK, ADA, and Nab assays, GM at ICON APAC, VP of bioanalysis/DMPK at Frontage (China).
Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Great China.
Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Great China.
Frontage Holdings Announces 2020 Interim Results
Various mitigation measures employed to minimize the adverse impact of the COVID-19 pandemic
Continued to enhance capacities and capabilities
Frontage receives “CRO Leadership Awards 2020” based on Quality and Reliability
Frontage Laboratories, Inc. has once again been named as a CRO Leadership Awards based on Quality and Reliablity recipient by Life Science Leader magazine.
Topic Selection: Delivery Modalities for Sterile Product Development of Poorly Water Soluble Drugs
Welcome everyone to our Frontage Laboratories Podcast. I’m your host, Bryan Newman. We appreciate you joining us today and hope you are all staying healthy and safe. Our topic that we will be covering is Delivery Modalities for Sterile Product Development of Poorly Water Soluble Drugs. I am joined today by our special guest Director of PD/CTM Manufacturing here at Frontage Laboratories, Manish Munjal.